Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment
2024年5月2日 - 11:19PM
ビジネスワイヤ(英語)
Ready-to-use kit expands range of bioanalysis
kits, and enables generic detection of immune complexes in rodent
samples
Gyros Protein Technologies AB, a pioneer in automated
nanoliter-scale immunoassays and a leading provider of peptide
synthesizers and reagents, today announced the introduction of
Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for
the detection of circulating immune complexes of human IgG with
rodent anti-human IgG. Validated for use with mouse and rat
samples, the Kit Reagents provide a ready-to-use solution to
accelerate screening of biotherapeutic drug candidates during
preclinical development, enabling immunogenicity assessment of drug
candidates without the need for drug-specific ADA assay
development.
The new Kit Reagents expedite bioanalysis by removing the need
for assay development and optimization across molecules to provide
robust, reproducible, reliable data from nanoliter sample volumes.
This is beneficial when ADA assessment is evaluated in preclinical
animal models where sample volume may be limited.
Monitoring of ADAs is essential in preclinical studies. Multiple
drug candidates are often evaluated in parallel using a small
number of animals to provide understanding of clearance profiles
and safety or efficacy issues resulting from immune complex
formation. The Gyrolab Generic Rodent ADA Kit fills an
industry-wide need for a generic assay solution to expedite
immunogenicity assessment.
The new bioanalysis kit is optimized for use on all Gyrolab
systems and complements the Company’s existing portfolio of
ready-to-use kits and solutions for pharmacokinetics and
toxicokinetics. Following the introduction of Gyrolab Generic Cyno
ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents
further expand the utility of the Gyrolab platform into earlier
drug screening and preclinical phases of development. Automation
with Gyrolab systems reduces variability due to manual pipetting
and speeds up workflows by generating 96 data points within 80
minutes, helping to accelerate the development of novel human IgG
therapeutics. Additionally, the Gyrolab platform supports the
development of drug-specific ADA assays in the later stages of drug
development, using automated acid dissociation in the Gyrolab
Mixing CD 96 and the dedicated Gyrolab ADA Software, enabling
immunogenicity assessment all the way from discovery through every
phase of clinical analysis.
Mark Vossenaar, General Manager, Biopharmaceutical
Development Division, Gyros Protein Technologies, commented:
“The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our
portfolio enhances our offering of ready-to-use kits and solutions
for use in drug screening and preclinical development.
Complementing our existing kits such as the Gyrolab Generic Cyno
ADA Kit Reagents for use in non-human primates and our extensive
offering in the pharmacokinetic and toxicokinetic bioanalysis
space, our open Gyrolab platform provides a powerful tool to
accelerate immunogenicity assessment at the preclinical stage."
For more information:
https://www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-rodent-ada-kit-reagents
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502170416/en/
Dr Ben Rutter Zyme Communications Email:
ben.rutter@zymecommunications.com